Compare Gilead Sciences, Inc. (GILD) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Gilead Sciences, Inc. trades at $149.66 (market cap $182.40B), while Vanguard Total Stock Market Index Fund ETF trades at $380.8 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 12.6× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Vanguard Total Stock Market Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Vanguard Total Stock Market Index Fund ETF for 131 Days on average.
| GILD | VTI | |
|---|---|---|
Market Cap | $182.40B | $2.30T |
Volume | 4,469,821 | 2,982,924 |
Sector | Health | — |
52-Week High | $155.80 | $384.30 |
52-Week Low | $116.74 | $311.68 |
Typical Hold Time | 111 Days | 131 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
VTI trades at $380.52, down slightly by 0.13% with a bullish technical signal from moving averages. The ETF maintains broad U.S. equity exposure across 3,500+ stocks, though concentration in top holdings remains significant. Recent news highlights long-term growth potential with $500 monthly investments since 2001 growing to approximately $876,000 according to Motley Fool (2026-10-01).
VTI offers diversified U.S. market access with low costs, suitable for long-term investors. Risks include market concentration in top holdings and broader economic sensitivity. Analyst sentiment remains positive for buy-and-hold strategies, though recent articles question the value added by small/mid-cap exposure versus S&P 500-focused alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
